Celgene is on a shopping spree to fill a looming revenue holeâ€”a sensible course of action. The trouble is, there is no guarantee their purchases will solve anything.
The biotech giant is in talks to acquire Juno Therapeutics, The Wall Street Journal reported Tuesday. This comes after Celgene announced the purchase of cancer startup Impact Biomedicines earlier this month for $1.1 billion upfront, plus significant milestone payments.
...  